- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 207/12
Total number of patents in this class: 715
10-year publication summary
|
36
|
58
|
41
|
47
|
54
|
39
|
35
|
42
|
36
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Sanofi | 4157 |
24 |
| Journey Medical Corporation | 95 |
20 |
| Bristol-myers Squibb Company | 4792 |
19 |
| Novartis AG | 10462 |
18 |
| Takeda Pharmaceutical Company Limited | 2715 |
17 |
| Bodor Laboratories, Inc. | 59 |
12 |
| Boehringer Ingelheim International GmbH | 4580 |
10 |
| F. Hoffmann-La Roche AG | 7879 |
9 |
| Merck Sharp & Dohme LLC | 3717 |
9 |
| Integrative Research Laboratories Sweden AB | 38 |
8 |
| Chiesi Farmaceutici S.p.A. | 962 |
7 |
| Recurium IP Holdings, LLC | 129 |
7 |
| Hoffmann-La Roche Inc. | 3628 |
6 |
| Alkermes Pharma Ireland Limited | 256 |
6 |
| Alnylam Pharmaceuticals, Inc. | 1160 |
6 |
| Astellas Pharma Inc. | 1048 |
6 |
| Cayman Chemical Company, Incorporated | 66 |
6 |
| Correvio International Sàrl | 20 |
6 |
| Gen1e Lifesciences Inc. | 30 |
6 |
| Centre National de La Recherche Scientifique | 10820 |
5 |
| Other owners | 508 |